|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2213703T5
(es)
|
2000-06-27 |
2011-11-02 |
Laboratorios S.A.L.V.A.T., S.A. |
Carbamatos derivados de arilalquilaminas.
|
|
EP1345937B1
(en)
|
2000-12-22 |
2005-09-28 |
Almirall Prodesfarma AG |
Quinuclidine carbamate derivatives and their use as m3 antagonists
|
|
ES2266291T3
(es)
|
2000-12-28 |
2007-03-01 |
Almirall Prodesfarma Ag |
Nuevos derivados de quinuclidina y composiciones medicinales que los contienen.
|
|
CA2470567A1
(en)
|
2001-12-14 |
2003-06-26 |
Targacept, Inc. |
Methods and compositions for treatment of central nervous system disorders
|
|
CN1832948B
(zh)
|
2001-12-20 |
2011-06-15 |
基耶西药品股份公司 |
1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
|
|
ES2203327B1
(es)
*
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
|
EP1546099B1
(en)
|
2002-07-08 |
2008-12-31 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
|
|
TWI295669B
(en)
|
2002-10-30 |
2008-04-11 |
Theravance Inc |
Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
EP1618091A1
(en)
|
2003-04-09 |
2006-01-25 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
NZ542952A
(en)
|
2003-04-11 |
2008-11-28 |
Ranbaxy Lab Ltd |
Azabicyclo derivatives as muscarinic receptor antagonists
|
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
US7358244B2
(en)
|
2003-05-28 |
2008-04-15 |
Theravance, Inc. |
Azabicycloalkane compounds
|
|
EP1644356A1
(en)
|
2003-07-11 |
2006-04-12 |
Theravance, Inc. |
Substituted 4-amino-1-benzylpiperidine compounds
|
|
ATE435855T1
(de)
|
2003-11-21 |
2009-07-15 |
Theravance Inc |
Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
WO2005087733A1
(en)
|
2004-03-11 |
2005-09-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2007528408A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
|
|
EP1723109A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
EP1723113A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200538095A
(en)
|
2004-03-11 |
2005-12-01 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7560469B2
(en)
|
2004-03-11 |
2009-07-14 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2007528416A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
ES2246170B1
(es)
*
|
2004-07-29 |
2007-04-01 |
Almirall Prodesfarma, S.A. |
Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
EP1856049A1
(en)
|
2005-03-10 |
2007-11-21 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7642355B2
(en)
|
2005-03-10 |
2010-01-05 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7629336B2
(en)
|
2005-03-10 |
2009-12-08 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200714587A
(en)
|
2005-03-10 |
2007-04-16 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7659403B2
(en)
|
2005-03-10 |
2010-02-09 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
WO2006138218A1
(en)
|
2005-06-13 |
2006-12-28 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
WO2007024814A1
(en)
|
2005-08-22 |
2007-03-01 |
Targacept, Inc. |
HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
|
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
|
EP1968980A1
(en)
*
|
2005-12-30 |
2008-09-17 |
Ranbaxy Laboratories, Ltd. |
Muscarinic receptor antagonists
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0602778D0
(en)
|
2006-02-10 |
2006-03-22 |
Glaxo Group Ltd |
Novel compound
|
|
PT2322525E
(pt)
|
2006-04-21 |
2013-12-26 |
Novartis Ag |
Derivados de purina para utilização como agonistas do recetor de adenosina a2a
|
|
ES2298049B1
(es)
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
|
EP1882691A1
(en)
|
2006-07-26 |
2008-01-30 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine derivatives as M3 antagonists
|
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
RU2441868C2
(ru)
*
|
2007-02-09 |
2012-02-10 |
Астеллас Фарма Инк. |
Аза-кольцевое соединение с внутренним мостиком
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
ES2361595T3
(es)
|
2007-05-07 |
2011-06-20 |
Novartis Ag |
Compuestos orgánicos.
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
EP2217597B1
(en)
|
2007-10-01 |
2011-03-30 |
Comentis, Inc. |
Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
|
|
EP2065385A1
(en)
*
|
2007-11-28 |
2009-06-03 |
Laboratorios SALVAT, S.A. |
Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
|
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
|
AU2009203693B2
(en)
|
2008-01-11 |
2012-06-07 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
|
EP2080507A1
(en)
*
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Pharmaceutical formulations comprising an anticholinergic drug
|
|
EP2254598B1
(en)
|
2008-02-13 |
2013-07-10 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|
|
US20100055045A1
(en)
|
2008-02-26 |
2010-03-04 |
William Gerhart |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
AU2009241628A1
(en)
|
2008-02-26 |
2009-11-05 |
Elevation Pharmaceuticals, Inc. |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
EP2300010B1
(en)
|
2008-06-10 |
2015-03-04 |
Novartis AG |
Pyrazine derivatives as epithelial sodium channel blockers
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
WO2010045633A2
(en)
*
|
2008-10-17 |
2010-04-22 |
National Jewish Health |
Measurement and analysis of leukotrienes
|
|
EP2206712A1
(en)
*
|
2008-12-23 |
2010-07-14 |
CHIESI FARMACEUTICI S.p.A. |
"Alkaloid aminoester derivatives and medicinal composition thereof"
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
IN2012DN01961A
(US20040106767A1-20040603-C00005.png)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
BR112012032330A2
(pt)
|
2010-06-22 |
2016-11-08 |
Chiesi Farma Spa |
formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
|
|
BR112012032332A2
(pt)
|
2010-06-22 |
2016-11-08 |
Chiesi Farma Spa |
composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
|
|
CN102947299B
(zh)
|
2010-06-22 |
2015-07-15 |
奇斯药制品公司 |
生物碱氨基酯衍生物及其药物组合物
|
|
RU2569846C2
(ru)
*
|
2010-06-22 |
2015-11-27 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Алкалоидные производные сложных аминоэфиров и включающие их лекарственные композиции
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
KR20130141534A
(ko)
*
|
2010-11-26 |
2013-12-26 |
키에시 파르마슈티시 엣스. 피. 에이. |
글리신 유도체 및 무스카린 수용체 길항제로서의 이들의 용도
|
|
KR101928505B1
(ko)
*
|
2011-01-28 |
2018-12-12 |
에스케이바이오팜 주식회사 |
피리돈 유도체 및 이를 포함하는 약학적 조성물
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US20120220557A1
(en)
|
2011-02-17 |
2012-08-30 |
Chiesi Farmaceutici S.P.A. |
Liquid propellant-free formulation comprising an antimuscarinic drug
|
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン， エルエルシー |
複素環化合物およびその使用
|
|
SG192795A1
(en)
|
2011-02-25 |
2013-09-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
EP3673906A1
(en)
*
|
2011-03-18 |
2020-07-01 |
Genzyme Corporation |
Glucosylceramide synthase inhibitors
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
EP2702041A1
(en)
|
2011-04-29 |
2014-03-05 |
Chiesi Farmaceutici S.p.A. |
Alkaloid ester and carbamate derivatives and medicinal compositions thereof
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US9174994B2
(en)
|
2011-11-23 |
2015-11-03 |
Intellikine, Llc |
Enhanced treatment regimens using mTor inhibitors
|
|
WO2013098145A1
(en)
|
2011-12-30 |
2013-07-04 |
Chiesi Farmaceutici S.P.A. |
Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
RU2660354C2
(ru)
|
2012-04-03 |
2018-07-05 |
Новартис Аг |
Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
KR20160141855A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
|
|
PT3134396T
(pt)
|
2014-04-24 |
2019-12-16 |
Novartis Ag |
Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
|
|
PL3134395T3
(pl)
|
2014-04-24 |
2018-07-31 |
Novartis Ag |
Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
|
JP2017524736A
(ja)
|
2014-07-11 |
2017-08-31 |
アルファーマゲン，エルエルシー |
アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
CN107207510B
(zh)
|
2014-07-31 |
2019-11-29 |
诺华股份有限公司 |
联合疗法
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
CN113891744A
(zh)
|
2019-06-10 |
2022-01-04 |
诺华股份有限公司 |
用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
|
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|
|
IL300090A
(en)
|
2020-07-24 |
2023-03-01 |
Genzyme Corp |
Pharmaceutical preparations containing VENGLUSTAT
|
